Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jun 14;18(6):e0281035. doi: 10.1371/journal.pone.0281035

Aqueous spice extracts as alternative antimycotics to control highly drug resistant extensive biofilm forming clinical isolates of Candida albicans

Bindu Sadanandan 1,*, Vaniyamparambath Vijayalakshmi 1, Priya Ashrit 1, Uddagiri Venkanna Babu 2, Lakavalli Mohan Sharath Kumar 2, Vasulingam Sampath 2, Kalidas Shetty 3, Amruta Purushottam Joglekar 1, Rashmi Awaknavar 1
Editor: Guadalupe Virginia Nevárez-Moorillón4
PMCID: PMC10266687  PMID: 37315001

Abstract

Candida albicans form biofilm by associating with biotic and abiotic surfaces. Biofilm formation by C. albicans is relevant and significant as the organisms residing within, gain resistance to conventional antimycotics and are therefore difficult to treat. This study targeted the potential of spice-based antimycotics to control C. albicans biofilms. Ten clinical isolates of C. albicans along with a standard culture MTCC-3017 (ATCC-90028) were screened for their biofilm-forming ability. C. albicans M-207 and C. albicans S-470 were identified as high biofilm formers by point inoculation on Trypticase Soy Agar (TSA) medium as they formed a lawn within 16 h and exhibited resistance to fluconazole and caspofungin at 25 mcg and 8 mcg respectively. Aqueous and organic spice extracts were screened for their antimycotic activity against C. albicans M-207 and S-470 by agar and disc diffusion and a Zone of Inhibition was observed. Minimal Inhibitory Concentration was determined based on growth absorbance and cell viability measurements. The whole aqueous extract of garlic inhibited biofilms of C. albicans M-207, whereas whole aqueous extracts of garlic, clove, and Indian gooseberry were effective in controlling C. albicans S-470 biofilm within 12 h of incubation. The presence of allicin, ellagic acid, and gallic acid as dominant compounds in the aqueous extracts of garlic, clove, and Indian gooseberry respectively was determined by High-Performance Thin Layer Chromatography and Liquid Chromatography-Mass Spectrometry. The morphology of C. albicans biofilm at different growth periods was also determined through bright field microscopy, phase contrast microscopy, and fluorescence microscopy. The results of this study indicated that the alternate approach in controlling high biofilm-forming, multi-drug resistant clinical isolates of C. albicans M-207 and S-470 using whole aqueous extracts of garlic, clove, and Indian gooseberry is a safe, potential, and cost-effective one that can benefit the health care needs with additional effective therapeutics to treat biofilm infections.

Introduction

Many Candida species are known to cause infections, but more than 90% of the cases are caused by Candida albicans [1]. C. albicans is a commensal yeast colonizing several niches in the body such as skin, hair, nail, oral cavity, gastrointestinal tract, and reproductive tract [25]. This organism remains asymptomatic with no apparent infection in the body of healthy individuals, unlike the immunocompromised patients hospitalized with serious conditions where it causes candidiasis [6, 7]. The severity of the infection can vary from superficial to invasive candidiasis. The latter may lead to 40% of bloodstream infections in clinical settings [3]. Candidiasis of the mucosae includes the oral and otitic cavities, esophageal, gastrointestinal, and reproductive tracts (vulvovaginitis in females, and balanitis in males). The incidence of C. albicans in denture wearers and in health conditions like HIV, acute leukaemia and patients in long term facilities are 50–65%, 95%, 90%, and 65–88% respectively [8].

C. albicans studied previously as planktonic cells are now studied in the biofilm form as it is now known to be in its natural state of growth [9]. The virulence of C. albicans is attributed to its ability to form a biofilm which is a mixed environment of microbial cells surrounded by an Extra Cellular Matrix (ECM) with distinct properties as compared to planktonic cells [1013]. The ECM formed around the biofilm acts as a barrier for the entry of antimycotic agents into the cells [14]. Most Candida species including C. albicans have developed resistance to the azole category of antifungals. However, recalcitrance to echinocandins like caspofungin is rarely found [15]. The resistance of C. albicans to these conventional drugs is a growing cause of concern for treatment involving biofilm infections. C. albicans grows on medical devices such as intravenous lines, drains, and catheters dwelling within the human body which are further responsible for many clinical manifestations leading to bloodstream infections [1, 16, 17]. These devices also serve as a substrate for their growth and are tough to treat with conventional antimycotics. The removal of such infected devices remains the only option to treat the complications [18]. Hence, additional therapeutics are required for the control of these biofilms within the human body.

New drug molecules from natural products are potential alternatives [19]. Almost 80% of the world’s population mainly relies on traditional medicines involving plant-based therapies according to WHO [20, 21]. Oral Candidiasis is one of the common oral mucosal infections and its management is usually very challenging either due to treatment failure or recurrence [22]. In this context, plant extracts more so water extracts with antimycotic properties can be potential alternatives as they are effective and non-toxic to the system [2326]. Garlic (Allium sativam L.), Clove (Syzygium aromaticum L.), and Indian Gooseberry (Phyllanthus emblica L.) have been explored in traditional medicine for potential therapeutics for conditions such as cancer, constipation, and other disease conditions [2730]. They have properties such as anti-inflammatory, anti-fungal, anti-bacterial, and antioxidant activities. Allicin, a sulfur compound predominantly present in garlic is one of the active constituents with known antimicrobial activity. Clove consists of eugenols, gallic acid derivatives, and many other phenolic compounds and flavonoids namely ellagic acid and salicylic acid which are responsible for the pharmacological properties [31]. Likewise, Indian gooseberry also possesses important cancer chemopreventive potential and many of the polyphenols such as gallic acid and ellagic acid are found in Indian gooseberry that could be responsible for their potential antimicrobial activity [32, 33]. It is one of the main components present in Triphala which is a concoction of three different ayurvedic medicines [34]. Garlic, gooseberry, and clove extracts have been previously studied for their biocompatibility [3538]. The cytotoxicity varies with the variety of spices used and the method of preparation of the extract [39]. Garlic has been used to treat and control many diseases like cardiovascular, blood pressure, metabolic disorders, etc [40, 41], and is also known to improve the symptoms in persons with various fatigues [42]. Gooseberry has proven to improve total cholesterol and triglyceride levels in dyslipidemia patients [43]. When studied in a rat model, a decrease in lipid peroxidation and an increase in glutathione peroxidase and catalase were observed when treated with clove extract [44]. Garlic extract stimulated ROS production which is beneficial for normal cells and fatal for cancer cells [39]. When garlic extract was studied on the KB cancer cell line, a 50% reduction in the cells was observed at a concentration greater than 100 μgmL-1 [45]. Similar results were observed in the Colo 205 cancer cell line [46]. Alexa et al studied the clove oil and showed concentration-dependent cell cytotoxicity on HaCaT, HGF A375, and SCC-4 cancer cells [47]. Indian gooseberry showed a cytotoxic effect above 100 μgmL-1 on HepG2 cancer cells [48].

The present study investigates the potential of spice extracts of garlic, clove, and Indian gooseberry in controlling high biofilm-forming multidrug-resistant clinical isolates and standard culture of C. albicans. The phytochemical profiling for each of these spice extracts was determined by LC-MS and HPTLC methods. MIC of the spice extracts was determined by broth microdilution and the structural characterization of the cultures was carried out by bright field, phase contrast, and fluorescence microscopic studies. This study is focused on exploring the potential of these spice extracts in controlling drug-resistant C. albicans and biofilm formation which can contribute to the potential of new natural therapeutics as antimycotic solutions.

Materials and methods

Cultures and identification

C. albicans MTCC-3017 (ATCC-90028) was procured from IMTECH (Chandigarh, India). Ten C. albicans clinical isolates; M-207 from the umbilical vein catheter of a female baby hospitalized in the Intensive Care Unit (ICU) for a month, M-529 from a vaginal swab of a female patient, S-470 from the sputum of a female patient, U-2647, U-3713, U-3800, U-3893, U-427, U-499 from the urine of female and male patients, D-4 from a dental sample of a male patient, were isolated from patients with invasive candidiasis. All the clinical isolates were isolated, identified, and kindly provided by The Department of Microbiology, M S Ramaiah Medical College and Teaching Hospital, Bengaluru, India. The identity of these isolates was further confirmed at our laboratory by the lactophenol cotton blue test [49], germ tube test [50], and colony morphology on CHROMAgar Candida [51].

The formation of biofilm was determined using a biofilm tube test [1].

Ethical clearance was not required for this study as no humans were directly involved.

Subculturing and maintenance of cultures

All the C. albicans isolates were sub-cultured in Malt Yeast Agar (MYA) plates and incubated at 37°C for 24 h. The isolates were stored as glycerol stocks (15%v/v) and maintained at -86°C. All the isolates were propagated in the required medium for further experiments.

Point inoculation

A loopful of the culture of each isolate was picked using an inoculation loop and inoculated at the center of the Tryptic Soy Agar (TSA) plate. The plates were incubated overnight at 37°C for 16 h.

In vitro induction of C. albicans biofilm and the effect of FBS on biofilm adhesion

Biofilm was induced on 96-well microtiter plates with some modifications in the protocol [52]. The cell density of the isolates was standardized to 106 cellsmL-1 using a hemocytometer count. A 100 μL volume of the culture was added to each well of the microtiter plate. The plates were incubated at 37°C for 90 min to allow the biofilm to adhere to the substratum. After 90 min, the cells were discarded and given a 1X Phosphate Buffered Saline (PBS) wash to remove the unadhered cells. A 100 μL volume of fresh medium was added and incubated for different time points. The growth absorbance was measured at 600 nm using a Biotek Synergy HT microtiter plate reader.

One set of the microtiter plates was pre-coated with Fetal Bovine Serum (FBS) while the other set was not pre-coated with FBS. For the pre-coating, 100 μL of FBS was added to each well and incubated at 37°C for 24 h, following which the FBS was discarded and the wells were washed with 200 μL of PBS. Biofilm was induced on both sets of the microtiter plates in different media, Malt Yeast Broth (MYB), Yeast Extract Peptone Dextrose (YEPD), Potato Dextrose Broth (PDB), Sabouraud Dextrose Broth (SDB), Yeast Mannitol Broth (YMB), Tryptic Soy Broth (TSB), and RPMI-1640.

Antimicrobial activity of spice extracts in controlling Candida biofilms

Preparation of aqueous and organic solvent spice extracts

The raw materials were procured locally and authenticated by The Department of Pharmacognosy, The Himalaya Drug Company, Makali, Bengaluru, India. The extracts were prepared using a previously established protocol [53]. The raw materials were washed thoroughly with tap water followed by a sterile water wash and then air-dried. Aqueous extracts of garlic and Indian gooseberry were prepared by crushing 10 g of the sample in 5 mL of sterile water in a pestle and mortar. An aqueous extract of clove was prepared by mixing 5 g of powdered clove with 10 mL of water. These samples were centrifuged at 10000 rpm for 10 min at 4°C. The supernatant was filtered using a Whatman filter paper and the whole aqueous extract was used for the study. The dilutions of extracts from 5–200 mgmL-1 were prepared for the experiments. The preparation of organic solvent extracts of garlic, clove, and Indian gooseberry involved the same process as followed for the preparation of aqueous extracts however organic solvents such as petroleum ether, ethyl acetate, chloroform, methanol, ethanol, and butanol were used instead of sterile water.

Agar diffusion assay to determine zone of inhibition

Agar well and disc diffusion assays were performed [19] for the aqueous and organic solvent extracts to determine the Zone of Inhibition (ZOI). Muller Hinton Agar (MHA) plates were prepared. An inoculum of 106 cellsmL-1 of the culture was spread evenly on the MHA surface. Even-sized wells were punched on the agar plates and sealed with 1% agarose. A 100 μL volume of the spice extracts was added into the wells, sealed, and incubated at 37°C for 16 h and the ZOI was observed the following day. Sterile distilled water and organic solvents were used as respective controls for aqueous and organic extracts.

Filter paper discs with a 5 mm diameter were supersaturated with the spice extracts and placed on MHA for disc diffusion assay. CLSI standard Fluconazole disc (25 mcg) and Caspofungin acetate (8 mcg) were used to compare the ZOI with aqueous and organic solvent extracts.

Broth microdilution assay to determine the minimum inhibitory concentration (MIC)

The protocol by [54] was used to determine the MIC by broth microdilution assay. A 100 μL volume of 106 cellsmL-1 was added to microtiter plates and incubated for 90 min at 37°C in an incubator for adhesion. After 90 min the cells were discarded and washed with 200 μL of 1X PBS. A 100 μL volume of fresh medium was added to the wells. A 50 μL volume of aqueous garlic, clove, and Indian gooseberry extracts with concentrations 0.05–10 mg (dry weight measurements) was used for the treatment, and sterile distilled water was used as the control. The microtiter plates were incubated for different time points from 0–24 h. Optical density was measured at 600 nm using a microtiter plate reader, based on which MIC50 was determined. Only aqueous extracts were evaluated from this stage onwards due to the superior antimycotic activity after ZOI assays.

MTT assay. To determine the viability of C. albicans isolates after treatment with aqueous extracts, an MTT assay was performed using the protocol [55]. After incubation in microtiter plates, the unadhered cells were removed by washing with 200 μL of 1X PBS. Following the wash, 50 μL of 5 mgmL-1 MTT was added to each well and incubated for 3 h at 37°C. After incubation, 150 μL of acidified isopropanol was added to each well to dissolve the formazan crystals formed in the wells. The absorbance was measured at 540 nm using a microplate reader.

Aqueous extracts of garlic, clove, and Indian gooseberry control biofilm induced on glass slide

The C. albicans M-207 and S-470 were grown in a Petri plate containing TSB media, with a glass slide immersed in it and treated with Garlic– 1 mg for C. albicans M-207 and Garlic- 1.25 mg, Clove– 0.215 mg and Indian Gooseberry- 0.537 mg for C. albicans S-470 at 24 h. Control plates were maintained in parallel. Visual reduction in the biofilm in the Petri plate and glass slide was recorded. The glass slide was further visualized under the microscope to confirm biofilm inhibition.

High-performance thin layer chromatography of fresh whole aqueous extracts of garlic, clove, and Indian gooseberry

HPTLC for whole aqueous extracts of garlic, clove, and Indian gooseberry was performed using Alliin, ellagic acid, and gallic acid respectively as standards. Butanol+2 –Isopropanol+ Acetic acid+ Water in the ratio of 3:1:1:1 [56], Toluene+ Ethyl acetate + Methanol+ Formic acid in the ratio of 3:3:0.8:0.2 [57] and Toluene + Glacial acetic acid + Ethyl acetate + Formic acid in the ratio of 2:2:4.5:0.5 were used as mobile phases for garlic, clove, and Indian gooseberry respectively. HPTLC of fresh whole aqueous extracts were developed at 254 nm and 366 nm and derivatized by spraying Ninhydrin (1 mgmL-1) and ferric chloride (10 mgmL-1) to confirm the presence of alliin, ellagic acid, and gallic acid in the fresh extracts of garlic, clove, and Indian gooseberry respectively. A 10x10 cm pre-coated silica gel 60 F254 TLC plate was used to develop the chromatogram for HPTLC. A CAMAG HPTLC system equipped with a sample applicator and linomat V, CAMAG TLC visualizer was used to capture the images.

Liquid chromatography-mass spectrometry of fresh whole aqueous extracts of garlic, clove, and Indian gooseberry

HPTLC was followed up with LC-MS for further confirmation of allicin, ellagic acid, and gallic acid based on the specific peaks of the standards and their molecular mass at the specified retention time.

A Shimadzu LC-20AD series pump, DUG-20A3 series degasser, and Luna C18 (250 X 4.6 mm, 5 um) phenomenex column were used for the chromatographic run. A 20 μL volume of aqueous extracts of garlic, clove, and Indian gooseberry was injected through SIL-HTC Shimadzu auto-sampler at ambient temperature achieved through CTO-10 AS VP column oven at 30°C, 40°C, and 40°C respectively. The mobile phase was delivered at a flow rate of 1 mLmin-1 with a splitter for 25 min for garlic, 38 min for clove, and 49 min for Indian gooseberry.

For the garlic extract, the mobile phase consisted of water (J.T.Baker brand) in pump A and acetonitrile (J.T.Baker brand) in pump B. The flow into the columns was as follows; 0.01 min-5% (pump B), 10 min-20% (pump B), 15 min-40% (pump B), 20 min-40% (pump B), 23 min-5% (pump B) and equilibrium for 2 min-5% (pump B). Peak separation was monitored at 210 nm using SPD-20A UV/VIS detector.

For the clove extract, the mobile phase consisting of water with 0.1% formic acid in pump A and methanol (J.T.Baker brand) in pump B was used. The gradient mobile phase flow into the column was as follows; 0.01 min-15% (pump B), 3 min-20% (pump B), 8 min-35% (pump B), 18 min-50% (pump B), 28 min-65% (pump B), 32 min-65% (pump B), 35 min-15% (pump B) and equilibrium for 3 min-15% (pump B). Peak separation was monitored at 254 nm and 215 nm.

For the Indian gooseberry extract too the mobile phase consisted of water with 0.1% formic acid in pump A and methanol in pump B. The gradient mobile phase flow into the column was as follows; 0.01 min-0% (pump B), 5 min-0% (pump B), 10 min-3% (pump B), 12 min-5% (pump B), 1 min-10% (pump B), 20 min-20% (pump B), 25 min-35% (pump B), 34 min-50% (pump B), 37 min-65% (pump B), 40 min-90% (pump B), 43 min-90% (pump B), 46 min-0% (pump B) and equilibrium for 3 min-0% (pump B). Peak separation was monitored at 275 nm.

Bright-field microscopy

In this study, two staining methods viz. Crystal violet (CV) and lactophenol cotton blue were used to visualize the effect of the spice extracts on C. albicans biofilms. C. albicans cultures were grown for different time intervals at 24, 48, 72, 96, 120 h, and 12 days in the TSB medium. Based on ZOI and MIC from initial studies, C. albicans M-207 treated with aqueous extract of garlic and C. albicans S-470 treated with aqueous extracts of garlic, clove, and Indian gooseberry were studied using bright-field microscopy and CV staining at 1, 3 17, 24, 48, 72, 96 and 120 h. Control samples were also observed and compared in parallel.

Crystal violet staining. Candida biofilms produced in TSB broth culture were smeared on a glass slide/coverslip and heat fixed. A few drops of 0.1% crystal violet solution prepared in distilled water were added to the glass slide and left for a minute. Excess stain was washed off using distilled water and blotted. The slides/coverslips were observed under a trinocular light microscope at 40X and 100X magnifications. Studies were performed at different time intervals.

Lactophenol cotton blue staining. The slides were prepared similarly to that of crystal violet staining. Instead of the crystal violet stain, lactophenol cotton blue was used. The results were observed under a trinocular optical microscope at 40X and 100X magnifications. Studies were performed at different time intervals.

Phase-contrast microscopy

Biofilm was induced on microtiter plates as described in the previous protocol. Cultures grown on 96 well plates were directly captured at 1, 3, 6, 12, 24, 48, 72, 96, and 120 h for control and aqueous garlic treated C. albicans M-207 and aqueous garlic, clove, and Indian gooseberry treated C. albicans S-470. Phase-contrast microscopic images of the biofilm from 1–120 h were captured at 20X magnification (ZEISS, Axio Vert.A1).

Fluorescence microscopy

Fluorescence microscopy was carried out for control and treatment samples using calcofluor white dye. Cultures were grown on a glass slide immersed in TSB medium with 1 mg of aqueous garlic extract for C. albicans M-207 and 1.25 mg of garlic extract, 0.215 mg of clove extract, and 0.537 mg of Indian gooseberry extract for C. albicans S-470 for 3, 6, 12 and 24 h. Control sets for both isolates were maintained in parallel. The glass slide was removed, and the heat fixed. A 200 μL volume of 1 mgmL-1 Calcofluor white dye (Fluka analytical, 18909-100ML-F) was added to the glass slide and left for a minute in dark. A 10% KOH solution was added on top of the Calcofluor dye and left for a minute and the excess stain was blotted. The images were captured at 20X magnification under the UV range at an excitation wavelength of 380 nm and emission wavelength of 475 nm using a Fluorescence microscope (ZEISS, Axio Vert.A1).

Statistical analysis

One-way ANOVA followed by Tukey’s multiple comparison tests was used to study the statistical significance between biofilm formation in microtiter plates coated with and without FBS.

Results and discussion

Cultures and identification

In this study, we have used a standard C. albicans culture along with 10 clinical isolates from several patients with invasive Candidiasis. These clinical isolates are local strains and are either high or low biofilm formers. Multiple identification tests were performed to re-confirm the cultures as C. albicans.

Lactophenol cotton blue. On staining with lactophenol cotton blue, the cells appear dark blue against a light blue background (S1 Fig) [58]. We can also observe the formation of pseudohyphae in some of the isolates. This is a basic identification test for fungi [59].

Germ tube test: We observed the growth of the germ tube in each of the isolates (S2 Fig). Germ tubes are associated with increased synthesis of protein and ribonucleic acid. Amongst all the Candida species, only C. albicans forms a germ tube. The germ tube and the filament formed are known to be associated with the virulence of the culture [60]. It is also known to induce filamentous growth in C. albicans and modulate its growth [61, 62].

CHROMAgar Candida. C. albicans isolates formed a greenish-blue colony when grown on CHROMAgar Candida medium [51, 63] (S3 Fig). CHROMAgar Candida test on a differential agar medium is used to identify different species of Candida as per the colour of the colony formed on the agar plate. The chromogenic β-glucosaminidase substrate in the medium is metabolized to give green colonies of C. albicans [64].

Biofilm tube test. C. albicans M-207, C. albicans M-529, C. albicans S-470, and C. albicans U-3800 showed a dark ring of crystal violet stain around the tubes and were categorized as high biofilm formers (S4 Fig). The biofilm tube test is an indicator of the formation of biofilm by the isolates. The thickness and intensity of the ring of crystal violet stain around the tube also to a certain extent indicates whether the isolate is a low, medium, or high biofilm former [65].

Point inoculation

It was observed that on point inoculation, C. albicans M-207 and C. albicans S-470 formed a lawn completely covering the Petri plate at 16 h on TSA medium (Fig 1) as compared to the standard culture MTCC-3017 and the other clinical isolates (S5 Fig). Hence, of the 11 isolates, C. albicans M-207 and C. albicans S-470 were identified as high biofilm formers and chosen for further studies. It was also observed that for the two cultures extensive biofilm was formed in the TSA medium as compared to YEPD (S6 Fig), and SDA (S7 Fig). Therefore, the TSA medium was used for further experiments. The experiment was performed to observe colony morphology and the ability of the organism to form biofilm on a solid substratum as previous studies have proven that the biofilm-forming capability is highly influenced by the culture medium chosen [10, 66, 67].

Fig 1. Point inoculation of C. albicans isolates.

Fig 1

(a) MTCC-3017, (b) C. albicans M-207, (c) C. albicans S-470 on TSA medium at 16 h.

In vitro induction of C. albicans biofilm and the effect of FBS on biofilm adhesion

Biofilm formation in non-FBS and FBS-coated microtiter plates in different media viz MYB (S8 Fig), YEPD (S9 Fig), PDB (S10 Fig), SDB (S11 Fig), YMB (S12 Fig), RPMI-1640 (S13 Fig) and TSB (Fig 2) indicated that FBS did not significantly affect cell adhesion and biofilm formation in C. albicans M207 and C. albicans S-470. We have previously reported that the FBS coating of microtiter plates did not affect cell adhesion and biofilm formation in some of the clinical isolates of C. albicans when grown in RPMI-1640 [68], whereas for the other isolates, FBS did play a significant role. We have also reported in our previous study with C. glabrata cultures where biofilm formation in the absence of FBS coating did not make any significant difference to the cell adhesion which is most vital during biofilm formation [69, 70]. FBS has conventionally been used to mimic the in vivo environment [7174]. It is known to provide growth factors, attachment factors, vital nutrients, and toxin scavengers that support the growth of biofilms [75]. However, there are also studies proving that FBS inhibits the growth of biofilm in Staphylococcus aureus [76]. In this study, strong adherence of C. albicans M-207 and S-470 isolates to the substrate material was observed even in the absence of FBS, hence, further studies were carried out without FBS coating.

Fig 2. Growth of C. albicans clinical isolates on FBS and non-FBS coated 96 well microtiter plate in TSB medium.

Fig 2

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

Growth of Candida biofilms in 96 well polystyrene plates was induced in TSB (Fig 3), RPMI-1640 (S14 Fig), and YEPD (S15 Fig). In the YEPD medium, beyond 24 h, the growth rate reduced, whereas, in RPMI-1640 and TSB the cultures grew steadily up to 48 h. The highest growth was observed in the TSB medium and therefore was chosen for further experiments. C. albicans is known to grow the best in YEPD, RPMI, TSB, and MYB media [10, 77, 78]. It was also observed that in TSB, the growth of C. albicans M-207, S-470, U-2647, U-3893, and U-499 reduced beyond 48 h, whereas in C. albicans MTCC-3017, U-3800, U-427, and D-4 it was beyond 60 h and for C. albicans M-529, and U-3713 after 72 h. This indicated that the growth of the C. albicans cultures is influenced by the choice of media and the culture strain. Previous studies have also shown that the choice of growth media plays a major role in adhesion and biofilm formation in vitro [10, 79]. Also, clinical isolates are known to behave differently from standard cultures [80]. This is attributed to several patient-specific factors such as the source of isolation, gender, age, rate of infection, etc.

Fig 3. Growth profile of C. albicans isolates in TSB medium for 0–72 h.

Fig 3

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

Adhesion to the substrate material is very important for biofilm formation. The structure, composition of the material, roughness, and hydrophobicity influences the adhesion [20]. Studies have proven that C. albicans forms biofilm quickly on the polypropylene material without any requirement of serum [81].

Antimycotic activity of spice extracts in controlling Candida albicans biofilms

Agar well and disc diffusion

Various aqueous and organic solvent extracts of Mint (Mentha arvensis L.) leaves Turmeric (Curcuma longa L.) rhizome, Lemon (Citrus x limon L.) fruit, Pepper (Piper nigrum L.) corn, Papaya (Carica papaya L.) seeds, Papaya leaves (Carica papaya L.), Onion (Allium cepa L.), Neem (Azadirachta indica A. Juss) leaves, Swallow root (Decalepis hamiltonii) rhizome (S16 Fig), Garlic (Allium sativam L.) cloves, Indian Gooseberry (Phyllanthus emblica L.) fruit, and Clove (Syzygium aromaticum L.) buds were tested for their antimycotic properties to control C. albicans biofilms, amongst which aqueous extracts of garlic, clove, and Indian gooseberry showed most promising results and the ZOI was measured (Fig 4, Table 1). The aqueous extract of lemon also showed a faint inhibition for C. albicans M-207.

Fig 4. Antimicrobial activity of aqueous extracts of garlic, clove, and Indian gooseberry with conventional antimycotics.

Fig 4

(1) Clove (43mg), (2) Garlic (200mg), (3) Indian Gooseberry (86mg) with (a) (4) Fluconazole (25mcg) (control) and (b) (4) Caspofungin (8mcg) (control) for (A) C. albicans M-207, (B) C. albicans S-470. Concentrations are expressed as dry weight measurements.

Table 1. Zone of inhibition for aqueous extracts of garlic, clove, Indian gooseberry, and standard antimycotic discs of fluconazole and caspofungin by disc diffusion method.
Spice extracts/ Conventional Antimycotics Zone of Inhibition (mm) for C. albicans M-207 Zone of Inhibition (mm) for C. albicans S-470
Garlic (200 mg dry weight) 6.5 8
Clove (43 mg dry weight) - 5
Indian Gooseberry (86 mg dry weight) - 4
Fluconazole (25mcg) - -
Caspofungin (8mcg) - -

Garlic and clove are basic spices used the world over. Indian gooseberry is used to prepare spiced pickles and chutneys in India and several other Asian countries. These spices have been used in traditional medicine for ages and are known to have antifungal properties against Candida [20, 82, 83]. Garlic has been proven to inhibit the growth of several bacterial species such as Lactobacillus acidophilus, Staphylococcus aureus, Pseudomonas aeruginosa, [84], Bacillus subtilis, etc. It has also been proven to inhibit C. albicans-E. coli co-cultures [70]. Clove has been used for culinary purposes and produces an essential oil that is used in perfumes, and flavoring and is known for its antimicrobial properties [85]. Indian gooseberry has been used as an anti-inflammatory, diuretic, and cough suppressant and is also known to have an anti-tumor effect [86]. ZOI is a clear zone observed around the region where the cultures do not grow, indicating their antimicrobial activity. It was observed that the chosen C. albicans cultures were resistant to fluconazole (25mcg) and caspofungin (8mcg) showing no ZOI as observed by the agar disc diffusion method showing no ZOI. The standard fluconazole and caspofungin discs were used as control. The aqueous and some of the organic solvent extracts of garlic, clove, and Indian gooseberry showed ZOI proving the strength of the extracts in controlling the biofilm (Fig 4, Table 1, S17 and S18 Figs, S1 Table). Aqueous extract of garlic was very effective in controlling C. albicans M-207 and C. albicans S-470, whereas aqueous extracts of clove and Indian gooseberry were effective only against C. albicans S-470. The Total Solid (TS) content was estimated for each of the extracts and was found to be 200 mg for garlic, 43 mg for clove, and 86 mg for Indian gooseberry (all dry weight measurements). Further, in the study only the aqueous extracts were considered in the study as they were more efficient in controlling C. albicans based on ZOI and also did not have any toxicity issues as opposed to the organic solvent extracts.

Another unique observation was that for C. albicans M-207 and C. albicans S-470 when treated with a low concentration of garlic extract, the morphology of the biofilm appeared to be creased. At higher concentrations, a clear zone of inhibition was observed around the wells and the biofilm formed away from the wells does not have the creased morphology and instead seems to be smooth (Fig 5).

Fig 5. Antimicrobial activity of aqueous garlic extract.

Fig 5

(a) garlic extract at 0.25mg—1.25mg (b) garlic extract at 2.5 mg– 200 mg (Neat) on MHA for (A) C. albicans M-207 & (B) C. albicans S-470. Concentrations expressed as dry weight measurements.

Broth microdilution to determine minimum inhibitory concentration (MIC)

The results showed that at 12 h a 50% reduction in growth was observed for C. albicans M-207 as measured by growth absorbance at 600 nm with concentrations of 1 mg garlic and 1.25 mg garlic, 0.215 mg clove, and 0.537 mg Indian gooseberry for C. albicans S-470 (Fig 6). The cultures were treated with different concentrations of garlic (0.25 mg-10 mg), clove (0.05 mg-0.537 mg), and Indian gooseberry (0.107 mg-4.3 mg), for 0–24 h. The least optical density measured at the least concentration of extracts for which there is a 50% reduction of cells is considered to be the MIC [87]. Minimum inhibitory concentration 50 (MIC50) is the most widely used and informative measure of a drug’s efficacy.

Fig 6. Antimicrobial activity of aqueous extracts of garlic, clove, and Indian gooseberry on 96 well microtiter plate.

Fig 6

(A) C. albicans M-207, (B) C. albicans S-470 at various concentrations and different time intervals by growth absorbance. All values are expressed as mean and standard deviation. The experiment was performed in triplicate. Concentrations are expressed as dry weight measurements.

MTT assay. MTT assay was performed to determine the viability of cells at MIC50. However, we have also carried out MTT at MIC concentrations lower and higher than MIC50 (Fig 7). MTT assay was used to quantify the metabolically active cells [88]. At MIC50, cell viability of 24.4% was observed for C. albicans M-207 when treated with garlic. Similarly, the viability of 26.9%, 29.9%, and 36.1% were observed when C. albicans S-470 was treated with garlic, clove, and Indian gooseberry respectively. MTT was also performed for 24 h and 48 h preformed biofilms of C. albicans M-207 and S-470 treated with garlic extract at different concentrations and incubation times. For 24 h preformed biofilm, the cell viability at MIC50 was 49.27% and 53.1% for C. albicans M-207 and S-470 respectively. For 48 h preformed biofilm, the cell viability was 50.49% and 56.57% for C. albicans M-207 and S-470 respectively. The percentage of cell viability was observed to be higher in the preformed biofilms as compared to the developing biofilms.

Fig 7.

Fig 7

Panel A: Antimicrobial activity of aqueous extracts of garlic, clove, and Indian gooseberry by MTT Assay. (A) C. albicans M-207, (B) C. albicans S-470 at different concentrations and at different time intervals. The values are expressed as mean and standard deviation. The assay was performed in triplicate. Concentrations are expressed as dry weight measurements. Panel B: Antimicrobial activity of aqueous extracts of garlic against preformed C. albicans biofilm by MTT Assay. (A) 24 h preformed biofilm of C. albicans M-207, (B) 24 h preformed biofilm of C. albicans S-470, (C) 48 h preformed biofilm of C. albicans M-207, (D) 48 h preformed biofilm of C. albicans S-470.

Aqueous extracts of garlic, clove, and Indian gooseberry control biofilm induced on glass

The decrease in the biofilm in the aqueous extract-treated glass Petri plates as compared to the control Petri plates can be observed not just under the microscope, but also visually by just looking at the glass microscopic slides in the Petri plates. A reduction in the turbidity can be observed in the Petri plates and glass slides treated with garlic extract for both C. albicans M-207 and C. albicans S-470 when compared with the control. The clove extract-treated Petri plate looks to be more turbid than the control, mostly due to the color of the clove extract. However, on careful observation, the edges of the slide appear to be clearer in comparison to the control (Fig 8).

Fig 8. Glass slides immersed in glass Petri plate containing C. albicans treated with garlic, clove, and Indian gooseberry.

Fig 8

(a) C. albicans Control, (b) Aqueous garlic treated, (c) Aqueous clove treated, (d) Aqueous Indian gooseberry treated (A) C. albicans M-207 and (B) C. albicans S-470.

Chemical profiling of aqueous spice extracts

The presence of a specific band at Rf: 0.38, Rf: 0.3, and Rf: 0.82 were observed adjacent to the standard markers of alliin, ellagic acid, and gallic acid in the track loaded with garlic, clove, and Indian gooseberry respectively that confirm the presence of the desired chemical compound in the fresh aqueous extracts used for the antimicrobial studies (Fig 9). Although ellagic and gallic acid are both present in clove and Indian gooseberry [89, 90], we considered ellagic acid as the standard for clove and gallic acid as the standard for Indian gooseberry, as the stability of ellagic acid is better in clove than in Indian gooseberry and also the gallic acid is present in more quantity in Indian gooseberry than in clove [91, 92]. TLC was observed under 254 nm and 366 nm (S19 Fig) and developed thereafter using spraying reagents.

Fig 9. HPTLC results of garlic, clove, and Indian gooseberry.

Fig 9

(A) Garlic extract derivatized with ninhydrin—Track 1: Garlic (Aq. Extract); Track 2: Alliin standard (Rf: 0.38), (B) Clove extract derivatized with ferric chloride—Track 1: Clove (Aq. Extract); Track 2: Ellagic acid standard (Rf: 0.3), (C) Indian Gooseberry extract derivatized with ferric chloride—Track 1: Indian Gooseberry (Aq. Extract); Track 2: Gallic acid standard (Rf: 0.82).

Conventional methods of extraction mostly involve the use of organic solvents like methanol, ethanol, acetone, etc, to understand and evaluate the pharmacological efficacy of the extracts. However, in our study, aqueous extracts were found to be more effective. Also, they are eco-friendly with no side effects as no organic solvents are used during the extraction. The process is also economical, and reproducible, requiring less process time with efficacy even at low concentrations of the crude aqueous extract.

The results of LCMS showed the presence of peaks for allicin, ellagic acid, and gallic acid for aqueous extracts of garlic, clove, and Indian gooseberry respectively. LC-MS was also performed to further confirm the presence of allicin, ellagic acid, and gallic acid based on the specific peaks observed for these phytochemicals and based on the molecular mass of these components at their specified retention time.

LC-MS for fresh aqueous garlic extract was performed and a peak was obtained at an RT of 19.79 min at 210 nm. The mass spectrometry at the same RT showed the presence of allicin that has undergone protonation (m+h), becoming a molecular ion with a molecular mass of 163.1 mz-1 as shown in Fig 10. Allicin, one of the potent compounds present only in garlic was used as a standard marker with a molecular weight of 162.27 gmL-1. When garlic is crushed, allicin, an organo-sulfur compound is formed from the precursor alliin in the presence of alliinase.

Fig 10. LC-MS spectra for crude fresh aqueous extract of garlic, clove, and Indian gooseberry.

Fig 10

LC-MS measured at 210 nm, 275 nm, and 254 nm respectively.

LC-MS of standard ellagic acid as well as the fresh aqueous clove extract revealed that the peak for the ellagic acid standard was observed at an RT of 23.44 at 254 nm with a molecular mass of 300.9 gmol-1. The LC-MS spectra for fresh aqueous clove extract at an RT of 23.54 at 254 nm showed the presence of ellagic acid with a molecular mass of 300.9 mz-1 indicating that the compound had undergone deprotonation (m-h), thus becoming a molecular ion (mz-1) as shown in Fig 10. Ellagic acid, with a molecular weight of 302.19 gmL-1 present in clove was used as the standard marker.

LC-MS of standard gallic acid was performed along with fresh aqueous Indian gooseberry extract at 275 nm. The peak for the gallic acid standard was observed at an RT of 18.69 with a molecular mass of the compound weighing 168.8 gmol-1. The LC-MS spectra for fresh aqueous Indian gooseberry extract at an RT of 18.73 showed the presence of gallic acid with a molecular mass of 168.6 mz-1 indicating that the compound had undergone deprotonation (m-h), thus becoming a molecular ion (mz-1) as shown in Fig 10. Gallic acid, present in Indian gooseberry with a molecular weight of 170.12gmL-1 was used as the standard marker.

Bright-field microscopy

Bright-field microscopy with crystal violet staining, one of the simplest optical microscopic techniques was used to observe growth and biofilm formation in C. albicans M207 and C. albicans S470 for up to 12 days without any spice extract treatment. An increase in pseudo hyphae and chlamydospores development with an increase in the incubation time of the cultures was observed (S20 Fig). Similar results were observed for bright field microscopy with lactophenol cotton blue staining as well (S21 Fig). Observation of cells at different stages of growth has been very important to understand any organism [93]. On treatment with aqueous spic extracts, there was an effective decrease in the number of cells in the treatment samples when compared to the control on 12 h of incubation (Fig 11). However, with an increase in incubation time, cell clusters forming pseudo hyphae, hyphae, and biofilm were observed. In a study with clove and lemongrass extracts a reduction in cells was observed at 48 h [32].

Fig 11. Microscopic images of crystal violet stained Candida biofilm on a glass slide.

Fig 11

Images captured at 100X magnification at different time intervals (a) 1 h, (b) 3 h, (c) 12 h, (d) 24 h, (e) 48 h, (f) 72 h, (g) 96 h (h) 120 h for (A) C. albicans M-207 control, (B) Aqueous garlic treated C. albicans M-207, (C) C. albicans S-470 control, (D) Aqueous garlic treated C. albicans S-470, (E) Aqueous clove treated C. albicans S-470, (F) Aqueous Indian gooseberry treated C. albicans S-470.

Phase-contrast microscopy

The control samples were denser with more biomass, whereas, in the treatment samples, a reduction in biomass was observed. Due to the dense biofilm, individual cells could not be observed in phase-contrast microscopy (Fig 12). However, it has the advantage that the cultures need not be stained as in bright field microscopy. This microscopic technique has been useful to study biofilm at different angles [9496]. However, [97] experienced that the phase-contrast image was not clear for their study. Hence to understand the cells better, higher magnification microscopy such as fluorescence microscopy was performed.

Fig 12. Phase-contrast microscopic images in 96 well microtiter plate.

Fig 12

Images captured at 20x magnification at different time intervals (a) 1 h, (b) 3 h, (c) 6 h, (d) 12 h, (e) 24 h, (f) 48 h, (g) 72 h (h) 96 h (i) 120 h for (A) C. albicans M-207 control, (B) Aqueous garlic treated C. albicans M-207 (1mg), (C) C. albicans S-470 control, (D) Aqueous garlic treated C. albicans S-470 (1.25mg), (E) Aqueous clove treated C. albicans S-470 (0.215mg), (F) Aqueous Indian gooseberry treated C. albicans S-470 (0.537mg). Concentrations are expressed as dry weight measurements.

Fluorescence microscopy

An increase in the fluorescence in the control sets of C. albicans M-207 and C. albicans S-470 was observed, with increased incubation periods of 3 h to 24 h as the calcofluor dye binds to the cell walls of C. albicans. The bright blue fluorescence background indicates that there was dense biofilm formed as observed in Fig 13, Panel A. Calcofluor white is a UV-excitable dye that contains polysaccharides with β1–3 and β1–4 linkages which bind to chitin and beta-glucan. It has been used extensively to stain fungal cell walls [52, 98]. At 6 h, the fluorescence begins to reduce indicating the reduction in the number of cells in the treated samples, however, there was a significant decrease in the number of cells at 12 h indicating that aqueous garlic extract was very effective in inhibiting C. albicans M-207. This was also confirmed by quantifying the fluorescent images using ImageJ software (Fig 13, Panel B). The intensity of the treated samples was less when compared to the control at all-time intervals, the most effective at 12 h of incubation. Aqueous extracts of garlic, clove, and Indian gooseberry were found to be effective in inhibiting C. albicans S-470. Amongst the three extracts, the aqueous extract of garlic was found to be most effective as compared to the aqueous extracts of clove and Indian gooseberry in inhibiting C. albicans S-470. Quantification of the images using ImageJ also showed the effectiveness of garlic when compared to other spice extracts on C. albicans S-470. At 12 h of incubation, garlic extract had the highest inhibitory effect against C. albicans S-470. However, the cells formed biofilm with an increase in ECM that can be seen as an increase in blue fluorescence at 24 h in the treated set probably suggesting that the efficacy of the extract could have been reduced. The increase in the ECM after 24 h can also be attributed to the persistent cells. These persistent cells are known to have higher resistance, survive any antimycotic agents and interestingly are sensitive to growth inhibition and produce new persistent cells [70, 99].

Fig 13. Fluorescence images of C. albicans stained with calcofluor white.

Fig 13

Panel A: Images captured at different time intervals (a) 3 h, (b) 6 h, (c) 12 h, (d) 24 h for (A) C. albicans M-207 control, (B) Aqueous garlic treated C. albicans M-207 (1mg), (C) C. albicans S-470 control, (D) Aqueous garlic treated C. albicans S-470 (1mg), (E) Aqueous clove treated C. albicans S-470 (0.215mg), (F) Aqueous Indian gooseberry treated C. albicans S-470 (0.537mg). All images were captured at 40x magnification. Concentrations are expressed as dry weight measurements. Panel B: Quantification of fluorescence intensity of C. albicans M-207 and S-470 treated with garlic, clove, and gooseberry at different time intervals analyzed by the fluorescence of the entire image using ImageJ.

Conclusions

Controlling multidrug resistant extensive biofilm forming pathogens is a challenge in clinical settings. In light of this, alternative methods to control these pathogens is an essential need. In this study a preventive and prognostic approach in controlling C. albicans biofilm, with spice extracts was undertaken. We have reported for the first time a simple and cost-effective method of whole aqueous extracts of garlic, clove and Indian gooseberry to control and inhibit C. albicans biofilm formation. The results of the study have revealed that FBS does not have a pertinent effect on cell adhesion and biofilm formation in high biofilm forming MDR strains of C. albicans, but the choice of culture media has a major influence on in vitro biofilm formation. Aqueous extracts of garlic, clove, and Indian gooseberry were effective in controlling biofilm formation with a minimum concentration of 1 mg garlic for C. albicans M-207 and 1.25 mg garlic, 0.215 mg clove and 0.537 mg Indian gooseberry for C. albicans S-470 at 12 h of incubation. Chemical profile analysis determined the presence of allicin, ellagic acid, and gallic acid in the aqueous extracts of garlic, clove, and Indian gooseberry respectively. Biochemical and structural characterization studies have demonstrated the reduction in cell numbers on treatment with aqueous spice extracts and confirmed the transition of cells from the adherent biofilm phenotype to sessile non biofilm type. These results are indicative of the effectiveness of the extracts even in their whole forms which could be potentially far more effective when purified. Thus, there is a high scope to translate the knowledge and outcomes from this study into developing novel therapeutic approaches to tackle the threat of C. albicans infection. This approach can also be further applied in developing other spice-based antimycotic therapeutics in the form of tablets/injections/powders/sprays/douches and catheters coated with spice extracts such as these targeted long-used spice extracts.

Supporting information

S1 Fig. Lactophenol cotton blue stained C. albicans.

(a) MTCC-3017, (b) U-427, (c) U-499, (d) U-3893, (e) M-207, (f) M-529, (g) S-470, (h) U-2647, (i) U-3800, (j) U-3713, (k) D4 at 24 h.

(TIF)

S2 Fig. Germ tube formation in C. albicans isolates.

(a) MTCC-3017, (b) M-207, (c) M-529, (d) S-470, (e) U-2647, (f) U-3713, (g) U-3800, (h) U-3893, (i) U-427, (j) U-499, and (k) D-4. The arrows indicate the germ tube formed by the isolates.

(TIF)

S3 Fig. C. albicans isolates grown on CHROMagar medium.

MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 were cultured.

(TIF)

S4 Fig. Biofilm tube test for C. albicans isolates.

MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4.

(TIF)

S5 Fig. Point inoculation of C. albicans isolates on TSA medium.

(a) U-427, (b) U-499, (c) U-2647, (d) U-3800, (e) U-3893, (f) U-3713, (g) M-529, and (h) D-4 at 16 h.

(TIF)

S6 Fig. Point inoculation of C. albicans isolates on YEPD medium.

MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 at 16 h.

(TIF)

S7 Fig. Point inoculation of C. albicans isolates on SDA medium.

MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 at 16 h.

(TIF)

S8 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in MYB medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S9 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in YEPD medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S10 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in PDB medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S11 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in SDB medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S12 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in YMB medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S13 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in RPMI-1640 medium.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S14 Fig. Growth profile of C. albicans isolates in RPMI-1640 for 0-72h.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S15 Fig. Growth profile of C. albicans isolates in Yeast Extract Peptone Dextrose for 0-72h.

All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

(TIF)

S16 Fig. Screening of spice extracts.

(a) (1) Clove (2) Papaya seeds (3) Indian Gooseberry (4) Onion (5) Water as control, (b) (1) Pudina (2) Pepper (3) Lemon (4) Garlic (5) Water as control, (c) Papaya leaf (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (d) Neem (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (e) Turmeric (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (f) Swallow root (1) 100 mgmL-1 (2) 150 mgmL-1 (3) 250 mgmL-1 (4) 500 mgmL-1 (5) Water as control. (A) C. albicans M-207 and (B) C. albicans S-470 biofilm.

(TIF)

S17 Fig. Zones of inhibition (mm) in well diffusion showing antimicrobial activity of garlic, clove and Indian gooseberry on MHA.

(A) C. albicans M-207 and (B) C. albicans S-470 by solvent extraction. (a) (1) Clove + Petroleum ether, (2) Clove + Ethyl Acetate, (3) Garlic + Petroleum ether, (4) Garlic + Ethyl Acetate, (5) Indian Gooseberry + Ethyl Acetate, (6) Indian Gooseberry + Petroleum ether, (7) Control (Water), (b) (1) Garlic + Chloroform, (2) Indian Gooseberry + Chloroform, (3) Clove + Chloroform, (4) Garlic + Methanol, (5) Indian Gooseberry + Methanol, (6) Clove + Methanol, (7) Control (Water) (c) (1) Garlic + Ethanol, (2) Indian Gooseberry + Ethanol, (3) Clove + Ethanol, (4) Garlic + Butanol, (5) Indian Gooseberry + Butanol, (6) Clove + Butanol, (7) Control (Water).

(TIF)

S18 Fig. Zones of inhibition (mm) in disc diffusion showing antimicrobial activity of garlic, clove and Indian gooseberry on MHA.

(A) C. albicans M-207 and (B) C. albicans S-470 by solvent extraction. (a) (1) Clove + Petroleum ether, (2) Clove + Ethyl Acetate, (3) Garlic + Petroleum ether, (4) Garlic + Ethyl Acetate, (5) Indian Gooseberry + Ethyl Acetate, (6) Indian Gooseberry + Petroleum ether, (7) Control (Water), (b) (1) Garlic + Chloroform, (2) Indian Gooseberry + Chloroform, (3) Clove + Chloroform, (4) Garlic + Methanol, (5) Indian Gooseberry + Methanol, (6) Clove + Methanol, (7) Control (Water (c) (1) Garlic + Ethanol, (2) Indian Gooseberry + Ethanol, (3) Clove + Ethanol,(4) Garlic + Butanol, (5) Indian Gooseberry + Butanol, (6) Clove + Butanol, (7) Control (Water).

(TIF)

S19 Fig. HPTLC of aqueous extracts of garlic, clove and Indian gooseberry.

(A) HPTLC of Aqueous garlic extract indicated as ASP (Allium sativum Pulp)—Track 1: ASP (Aq. extract); Track 2: Alliin standard, (B) HPTLC of Aqueous clove extract indicated as SAFB (Syzygium aromaticum Flower Bud)—Track 1: SAFB; Track 2: Ellagic acid standard, (C) HPTLC of Aqueous gooseberry extract indicated as EOF (Emblica officinalis Fruit)—Track 1: EOF; Track 2: Gallic acid standard, at (a) 254 nm and (b) 366 nm.

(TIF)

S20 Fig. Microscopic images of crystal violet stained C. albicans.

(A) C. albicans M-207, (B) C. albicans S-470 induced on coverslip in TSB medium for (a) 24h, (b) 48h, (c) 72h, (d) 96h, (e) 120h, (f) 12days at 40X & 100X magnifications.

(TIF)

S21 Fig. Microscopic images of Lactophenol cotton blue stained stained C. albicans.

(A) C. albicans M-207, (B) C. albicans S-470 induced on coverslip in TSB medium for (a) 24h, (b) 48h, (c) 72h, (d) 96h, (e) 120h, (f) 12days at 40X & 100X magnifications.

(TIF)

S1 Table. Zone of inhibition for solvent extractions of garlic, clove, and Indian gooseberry by well diffusion method.

The solvents used were petroleum ether, ethyl acetate, chloroform, methanol, ethanol, and butanol.

(PDF)

Acknowledgments

The authors wish to thank Dr. Beena, Dr. Rameez Raja, and Dr. Indumathi from Microbiology Lab at Ramaiah Teaching Hospital, Bengaluru for providing us with the C. albicans clinical isolates.

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This research was funded by DEPARTMENT OF SCIENCE AND TECHNOLOGY (DST), Government of India, grant number SR/FT/LS-124/2012 to Bindu Sadanandan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. URL: https://dst.gov.in/.

References

  • 1.Janakiram B, Myneni RB, Kumar KA, Gousia S, Latha JNL. Methods of Determination of Biofilm Formation by Candida albicans. Res J Microbiol. 2016;12: 90–96. doi: 10.3923/JM.2017.90.96 [DOI] [Google Scholar]
  • 2.Heintz-Buschart A, Eickhoff H, Hohn E, Bilitewski U. Identification of inhibitors of yeast-to-hyphae transition in Candida albicans by a reporter screening assay. J Biotechnol. 2013;164: 137–142. doi: 10.1016/j.jbiotec.2012.12.004 [DOI] [PubMed] [Google Scholar]
  • 3.Fox E, Nobile C. The Role of Candida albicans Biofilms in Human Disease. Candida albicans Symptoms, Causes Treat Options. 2013; 1–24. https://www.researchgate.net/publication/257921622
  • 4.Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden Killers: Human Fungal Infections. Sci Transl Med. 2012;4: 165rv13–165rv13. doi: 10.1126/scitranslmed.3004404 [DOI] [PubMed] [Google Scholar]
  • 5.Mokhtar M, Rismayuddin NAR, Mat Yassim AS, Ahmad H, Abdul Wahab R, Dashper S, et al. Streptococcus salivarius K12 inhibits Candida albicans aggregation, biofilm formation and dimorphism. 2021;37: 767–776. doi: 10.1080/08927014.2021.1967334 [DOI] [PubMed] [Google Scholar]
  • 6.Kumamoto CA, Gresnigt MS, Hube B. The gut, the bad and the harmless: Candida albicans as a commensal and opportunistic pathogen in the intestine. Curr Opin Microbiol. 2020;56: 7–15. doi: 10.1016/j.mib.2020.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Espinel-Ingroff A, Canton E, Peman J, Rinaldi MG, Fothergill AW. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 document) in three laboratories: Results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J Clin Microbiol. 2009;47: 2766–2771. doi: 10.1128/JCM.00654-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Patil S, Rao RS, Majumdar B, Anil S. Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front Microbiol. 2015;6. doi: 10.3389/fmicb.2015.01391 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nobile CJ, Johnson AD. Candida albicans Biofilms and Human Disease. 2015;69: 71–92. doi: 10.1146/ANNUREV-MICRO-091014-104330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Weerasekera MM, Wijesinghe GK, Jayarathna TA, Gunasekara CP, Fernando N, Kottegoda N, et al. Culture media profoundly affect Candida albicans and Candida tropicalis growth, adhesion and biofilm development. Mem Inst Oswaldo Cruz. 2016;111: 697–702. doi: 10.1590/0074-02760160294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Kolter R, Greenberg EP. The superficial life of microbes. Nat 2006 4417091. 2006;441: 300–302. doi: 10.1038/441300a [DOI] [PubMed] [Google Scholar]
  • 12.Mitchell KF, Zarnowski R, Andes DR. Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions. PLOS Pathog. 2016;12: e1005828. doi: 10.1371/journal.ppat.1005828 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Staniszewska M. Virulence Factors in Candida species. Curr Protein Pept Sci. 2019;21: 313–323. doi: 10.2174/1389203720666190722152415 [DOI] [PubMed] [Google Scholar]
  • 14.Cruz-Claure MLD la, Cèspedes-Llave AA, Ulloa MT, Benito-Lama M, Domínguez-Álvarez E, Bastida A. Inhibition–Disruption of Candida glabrata Biofilms: Symmetrical Selenoesters as Potential Anti-Biofilm Agents. Microorg 2019, Vol 7, Page 664. 2019;7: 664. doi: 10.3390/microorganisms7120664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61: S612–S617. doi: 10.1093/cid/civ791 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Richardson JP, Moyes DL. Adaptive immune responses to Candida albicans infection. 2015;6: 327–337. doi: 10.1080/21505594.2015.1004977 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3: 685–702. doi: 10.1016/s1473-3099(03)00801-6 [DOI] [PubMed] [Google Scholar]
  • 18.Chan AKY, Tsang YC, Chu CH, Tsang CSP. Aspirin as an Antifungal-Lock Agent in Inhibition of Candidal Biofilm Formation in Surgical Catheters. Infect Drug Resist. 2021;14: 1427. doi: 10.2147/IDR.S308262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: A review. J Pharm Anal. 2016;6: 71–79. doi: 10.1016/j.jpha.2015.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Thaweboon B, Thaweboon S. Effect of Phyllanthus emblica Linn. on candida adhesion to oral epithelium and denture acrylic. Asian Pac J Trop Med. 2011;4: 41–45. doi: 10.1016/S1995-7645(11)60029-1 [DOI] [PubMed] [Google Scholar]
  • 21.Castillo-Pérez LJ, Alonso-Castro AJ, Fortanelli-Martínez J, Carranza-Álvarez C. Biotechnological approaches for conservation of medicinal plants. Phytomedicine. 2021; 35–58. [Google Scholar]
  • 22.Darwazeh AMG, Darwazeh TA. What Makes Oral Candidiasis Recurrent Infection? A Clinical View. J Mycol. 2014;2014: 1–5. doi: 10.1155/2014/758394 [DOI] [Google Scholar]
  • 23.Bansal V, Gupta M, Bhaduri T, Shaikh SA, Sayed FR, Bansal V, et al. Assessment of Antimicrobial Effectiveness of Neem and Clove Extract Against Streptococcus mutans and Candida albicans: An In vitro Study. Niger Med J. 2019;60: 285. doi: 10.4103/nmj.NMJ_20_19 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Soliman S, Alnajdy D, El-Keblawy AA, Mosa KA, Khoder G, Noreddin AM. Plants’ Natural Products as Alternative Promising Anti-Candida Drugs. Pharmacogn Rev. 2017;11: 104. doi: 10.4103/phrev.phrev_8_17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Said MM, Watson C, Grando D. Garlic alters the expression of putative virulence factor genes SIR2 and ECE1 in vulvovaginal C. albicans isolates. Sci Rep. 2020;10. doi: 10.1038/s41598-020-60178-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Watson CJ, Grando D, Fairley CK, Chondros P, Garland SM, Myers SP, et al. The effects of oral garlic on vaginal candida colony counts: a randomised placebo controlled double-blind trial. BJOG. 2014;121: 498–506. doi: 10.1111/1471-0528.12518 [DOI] [PubMed] [Google Scholar]
  • 27.Li G, Ma X, Deng L, Zhao X, Wei Y, Gao Z, et al. Fresh Garlic Extract Enhances the Antimicrobial Activities of Antibiotics on Resistant Strains in Vitro. Jundishapur J Microbiol. 2015;8: 1–6. doi: 10.5812/jjm.14814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Selvamuthukumaran M. Amla (Indian Gooseberry): Characteristics, Therapeutic Potential, and Its Value Addition. Asian Berries. 2020; 363–380.
  • 29.Bora P. Role of indian herbs in Boosting Immunity. Immun Boost Funct Foods to Combat COVID-19. 2021; 61–74. doi: 10.1201/9781003242604-6/ROLE-INDIAN-HERBS-BOOSTING-IMMUNITY-PREETI-BORA [DOI] [Google Scholar]
  • 30.Gupta E, Mishra P. Functional Food with Some Health Benefits, So Called Superfood: A Review. Curr Nutr Food Sci. 2020;17: 144–166. doi: 10.2174/1573401316999200717171048 [DOI] [Google Scholar]
  • 31.Cortés-Rojas DF, de Souza CRF, Oliveira WP. Clove (Syzygium aromaticum): a precious spice. Asian Pac J Trop Biomed. 2014;4: 90–96. doi: 10.1016/S2221-1691(14)60215-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Khan MS, Qais FA, Ahmad I. Indian Berries and Their Active Compounds: Therapeutic Potential in Cancer Prevention. New Look to Phytomedicine Adv Herb Prod as Nov Drug Leads. 2019; 179–201. [Google Scholar]
  • 33.Zhao T, Sun Q, Marques M, Witcher M. Anticancer properties of phyllanthus emblica (indian gooseberry). Oxid Med Cell Longev. 2015;2015. doi: 10.1155/2015/950890 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Peterson CT, Denniston K, Chopra D. Therapeutic uses of triphala in ayurvedic medicine. J Altern Complement Med. 2017;23: 607–614. doi: 10.1089/acm.2017.0083 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rath K, Sen S. Garlic extract based preparation of size controlled superparamagnetic hematite nanoparticles and their cytotoxic applications. IJBT Vol18(2) [April 2019]. 2019;18: 108–118. Available: http://nopr.niscpr.res.in/handle/123456789/49667 [Google Scholar]
  • 36.González-Locarno M, Pautt YM, Albis A, López EF, Tovar CDG. Assessment of Chitosan-Rue (Ruta graveolens L.) Essential Oil-Based Coatings on Refrigerated Cape Gooseberry (Physalis peruviana L.) Quality. Appl Sci 2020, Vol 10, Page 2684. 2020;10: 2684. doi: 10.3390/APP10082684 [DOI] [Google Scholar]
  • 37.Kumar A, Kanwar R, Mehta SK. Development of Phosphatidylcholine/Tween 80 based biocompatible clove oil-in-water nanoemulsion as a green nanocarrier for controlled herbicide delivery. Environ Pollut. 2022;293: 118558. doi: 10.1016/j.envpol.2021.118558 [DOI] [PubMed] [Google Scholar]
  • 38.El-Refai AA, Ghoniem GA, El-Khateeb AY, Hassaan MM. Eco-friendly synthesis of metal nanoparticles using ginger and garlic extracts as biocompatible novel antioxidant and antimicrobial agents. J Nanostructure Chem. 2018;8: 71–81. doi: 10.1007/S40097-018-0255-8/TABLES/4 [DOI] [Google Scholar]
  • 39.Szychowski KA, Binduga UE, Rybczyńska-Tkaczyk K, Leja ML, Gmiński J. Cytotoxic effects of two extracts from garlic (Allium sativum L.) cultivars on the human squamous carcinoma cell line SCC-15. Saudi J Biol Sci. 2018;25: 1703. doi: 10.1016/j.sjbs.2016.10.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. J Nutr. 2006;136. doi: 10.1093/jn/136.3.736S [DOI] [PubMed] [Google Scholar]
  • 41.Ansary J, Forbes-Hernández TY, Gil E, Cianciosi D, Zhang J, Elexpuru-Zabaleta M, et al. Potential Health Benefit of Garlic Based on Human Intervention Studies: A Brief Overview. Antioxidants. 2020;9: 1–35. doi: 10.3390/antiox9070619 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Morihara N, Nishihama T, Ushijima M, Ide N, Takeda H, Hayama M. Garlic as an anti-fatigue agent. Mol Nutr Food Res. 2007;51: 1329–1334. doi: 10.1002/mnfr.200700062 [DOI] [PubMed] [Google Scholar]
  • 43.Upadya H, Prabhu S, Prasad A, Subramanian D, Gupta S, Goel A. A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia. BMC Complement Altern Med. 2019;19: 1–14. doi: 10.1186/S12906-019-2430-Y/TABLES/2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ahmad T, Shinkafi TS, Routray I, Mahmood A, Ali S. Aqueous Extract of Dried Flower Buds of Syzygium aromaticum Inhibits Inflammation and Oxidative Stress. J Basic Clin Pharm. 2012;3: 323. doi: 10.4103/0976-0105.103813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Babu B, Sunil A, Mukunda A, Pynadath M, Mohan A, Aswathy. Anti-cancer potency of garlic (Allium sativum) extract in comparison to 5-fluorouracil-An in vitro study. 2020.
  • 46.Su CC, Chen GW, Tan TW, Lin JG, Chung JG. Crude extract of garlic induced caspase-3 gene expression leading to apoptosis in human colon cancer cells. In Vivo. 2006;20: 85–90. Available: https://europepmc.org/article/med/16433033 [PubMed] [Google Scholar]
  • 47.Alexa VT, Galuscan A, Soica CM, Cozma A, Coricovac D, Borcan F, et al. In Vitro Assessment of the Cytotoxic and Antiproliferative Profile of Natural Preparations Containing Bergamot, Orange and Clove Essential Oils. Molecules. 2022;27. doi: 10.3390/molecules27030990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Shivananjappa MM, Joshi MK. Influence of Emblica officinalis aqueous extract on growth and antioxidant defense system of human hepatoma cell line (HepG2). Pharm Biol. 2012;50: 497–505. doi: 10.3109/13880209.2011.618501 [DOI] [PubMed] [Google Scholar]
  • 49.Leck A. Preparation of Lactophenol Cotton Blue Slide Mounts. Community Eye Heal. 1999;12: 24. [PMC free article] [PubMed] [Google Scholar]
  • 50.Sheppard DC, Locas MC, Restieri C, Laverdiere M. Utility of the germ tube test for direct identification of Candida albicans from positive blood culture bottles. J Clin Microbiol. 2008;46: 3508–3509. doi: 10.1128/JCM.01113-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Nadeem SG, Hakim ST, Kazmi SU. Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings. Libyan J Med. 2010;5: 1–6. doi: 10.3402/ljm.v5i0.2144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol. 2001;183: 5385–5394. doi: 10.1128/JB.183.18.5385-5394.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Dahiya P, Purkayastha S. Phytochemical Screening and Antimicrobial Activity of Some Medicinal Plants Against Multi-drug Resistant Bacteria from Clinical Isolates. Indian J Pharm Sci. 2012;74: 443. doi: 10.4103/0250-474X.108420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Nagashima M, Yamagishi Y, Mikamo H. Antifungal susceptibilities of Candida species isolated from the patients with vaginal candidiasis. J Infect Chemother. 2016;22: 124–126. doi: 10.1016/j.jiac.2015.08.008 [DOI] [PubMed] [Google Scholar]
  • 55.Trafny EA, Lewandowski R, Zawistowska-Marciniak I, Stępińska M. Use of MTT assay for determination of the biofilm formation capacity of microorganisms in metalworking fluids. World J Microbiol Biotechnol 2013 299. 2013;29: 1635–1643. doi: 10.1007/s11274-013-1326-0 [DOI] [PubMed] [Google Scholar]
  • 56.Singh SP, Bajpai MK, Razdan B. Synthesis and study of anti-bacterial activity of complexes of diallyldisulphide from garlic. Int J Green Pharm. 2012;6: 180–183. doi: 10.4103/0973-8258.104927 [DOI] [Google Scholar]
  • 57.Ladva BJ, Mahida VM, Kantaria UD, Gokani RH. Marker based standardization of polyherbal formulation (SJT-DI-02) by high performance thin layer chromatography method. J Pharm Bioallied Sci. 2014;6: 213. doi: 10.4103/0975-7406.135249 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Mosca CO, Moragues MD, Llovo J, Al Mosaid A, Coleman DC, Pontón J. Casein agar: A useful medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol. 2003;41: 1259–1262. doi: 10.1128/JCM.41.3.1259-1262.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Mumuney KT, Abalaka ME. Comparative Study of Vaginal Candidiasis in Pregnant and Non-Pregnant Women Attending Ibrahim Badamasi Babangida Specialist Hospital and General Hospital, Minna Niger State, Nigeria. J Adv Microbiol. 2019;14: 1–7. doi: 10.9734/JAMB/2019/45762 [DOI] [Google Scholar]
  • 60.Munin E, Giroldo LM, Alves LP, Costa MS. Study of germ tube formation by Candida albicans after photodynamic antimicrobial chemotherapy (PACT). J Photochem Photobiol B Biol. 2007;88: 16–20. doi: 10.1016/j.jphotobiol.2007.04.011 [DOI] [PubMed] [Google Scholar]
  • 61.Ahmed R, Kodgire S, Santhakumari B, Patil R, Kulkarni M, Zore G. Serum responsive proteome reveals correlation between oxidative phosphorylation and morphogenesis in Candida albicans ATCC10231. J Proteomics. 2018;185: 25–38. doi: 10.1016/j.jprot.2018.06.018 [DOI] [PubMed] [Google Scholar]
  • 62.Truong T, Zeng G, Lim TK, Cao T, Pang LM, Lee YM, et al. Proteomics Analysis of Candida albicans dnm1 Haploid Mutant Unraveled the Association between Mitochondrial Fission and Antifungal Susceptibility. Proteomics. 2020;20: 1900240. doi: 10.1002/pmic.201900240 [DOI] [PubMed] [Google Scholar]
  • 63.Mulet Bayona J V., Salvador García C, Tormo Palop N, Gimeno Cardona C. Evaluation of a novel chromogenic medium for Candida spp. identification and comparison with CHROMagar Candida for the detection of Candida auris in surveillance samples. Diagn Microbiol Infect Dis. 2020;98: 115168. doi: 10.1016/J.DIAGMICROBIO.2020.115168 [DOI] [PubMed] [Google Scholar]
  • 64.Cooke VM, Miles RJ, Price RG, Midgley G, Khamri W, Richardson AC. New Chromogenic Agar Medium for the Identification of Candida spp. Appl Environ Microbiol. 2002;68: 3622. doi: 10.1128/AEM.68.7.3622-3627.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Mathur T, Singhal S, Khan S, Upadhyay D, Fatma T, Rattan A. Detection of Biofilm Formation Among The Clinical Isolates of Staphylococci: An Evaluation of Three Different Screening Methods. Indian J Med Microbiol. 2006;24: 25–29. doi: 10.4103/0255-0857.19890 [DOI] [PubMed] [Google Scholar]
  • 66.Terraf MCL, Tomás MSJ, Nader-Macías MEF, Silva C. Screening of biofilm formation by beneficial vaginal lactobacilli and influence of culture media components. J Appl Microbiol. 2012;113: 1517–1529. doi: 10.1111/j.1365-2672.2012.05429.x [DOI] [PubMed] [Google Scholar]
  • 67.Nadeem SG, Shafiq A, Hakim ST, Anjum Y, Kazm SU, Nadeem SG, et al. Effect of Growth Media, pH and Temperature on Yeast to Hyphal Transition in Candida albicans. Open J Med Microbiol. 2013;3: 185–192. doi: 10.4236/OJMM.2013.33028 [DOI] [Google Scholar]
  • 68.Sadanandan B, Vaniyamparambath V, Lokesh KN, Shetty K, Joglekar AP, Ashrit P, et al. Candida albicans biofilm formation and growth optimization for functional studies using response surface methodology. J Appl Microbiol. 2021;132: 3277–3292. doi: 10.1111/jam.15402 [DOI] [PubMed] [Google Scholar]
  • 69.Sadanandan B, Ashrit P, Nataraj LK, Shetty K, Jogalekar AP, Vaniyamparambath V, et al. High throughput comparative assessment of biofilm formation of Candida glabrata on polystyrene material. Korean J Chem Eng 2022. 2022;38: 1–10. doi: 10.1007/S11814-021-1054-3 [DOI] [Google Scholar]
  • 70.Ashrit P, Sadanandan B, Shetty K, Vaniyamparambath V. Polymicrobial Biofilm Dynamics of Multidrug-Resistant Candida albicans and Ampicillin-Resistant Escherichia coli and Antimicrobial Inhibition by Aqueous Garlic Extract. Antibiot (Basel, Switzerland). 2022;11. doi: 10.3390/antibiotics11050573 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Kucharíková S, Neirinck B, Sharma N, Vleugels J, Lagrou K, Van Dijck P. In vivo Candida glabrata biofilm development on foreign bodies in a rat subcutaneous model. J Antimicrob Chemother. 2015;70: 846–856. doi: 10.1093/jac/dku447 [DOI] [PubMed] [Google Scholar]
  • 72.Thein ZM, Samaranayake YH, Samaranayake LP. Dietary sugars, serum and the biocide chlorhexidine digluconate modify the population and structural dynamics of mixed Candida albicans and Escherichia coli biofilms. APMIS. 2007;115: 1241–1251. doi: 10.1111/j.1600-0643.2007.00735.x [DOI] [PubMed] [Google Scholar]
  • 73.Bliss JM, Tollefson GA, Cuevas A, Longley SJ, Neale MN, Uzun A, et al. Transcription Profiles Associated with Inducible Adhesion in Candida parapsilosis. mSphere. 2021;6. doi: 10.1128/mSphere.01071-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Kipanga PN, Luyten W. Influence of serum and polystyrene plate type on stability of Candida albicans biofilms. J Microbiol Methods. 2017;139: 8–11. doi: 10.1016/j.mimet.2017.04.006 [DOI] [PubMed] [Google Scholar]
  • 75.Yang H, Lim YH, Yun S, Yoon AY, Kim H. A Role of Cell Adhesion Molecules and Gelatinases in Human Serum-Induced Aggregation of Human Eyelid-Derived Stem Cells In Vitro. Dev Reprod. 2013;17: 409. doi: 10.12717/DR.2013.17.4.409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Abraham NM, Jefferson KK. A low molecular weight component of serum inhibits biofilm formation in Staphylococcus aureus. Microb Pathog. 2010;49: 388. doi: 10.1016/j.micpath.2010.07.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Moore JE, McMullan R. Comparison of media for optimal recovery ofCandida albicans andCandida glabrata from blood culture. Irish J Med Sci 2003 1722. 2003;172: 60–62. doi: 10.1007/BF02915247 [DOI] [PubMed] [Google Scholar]
  • 78.Singh M, Alka, Lee KE, Kumar P, Kang SG. Curcuma Turmeric Oil Enhanced Anti-Dermatophytic Drug Activity Against Candida albicans and Trichophyton mentagrophytes. Curr Drug Deliv. 2021;18: 1459–1469. doi: 10.2174/1567201818666210729105220 [DOI] [PubMed] [Google Scholar]
  • 79.Leonhard M, Zatorska B, Moser D, Tan Y, Schneider-Stickler B. Evaluation of combined growth media for in vitro cultivation of oropharyngeal biofilms on prosthetic silicone. J Mater Sci Mater Med 2018 294. 2018;29: 1–8. doi: 10.1007/s10856-018-6051-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Alnuaimi AD, O’Brien-Simpson NM, Reynolds EC, McCullough MJ. Clinical isolates and laboratory reference Candida species and strains have varying abilities to form biofilms. FEMS Yeast Res. 2013;13: 689–699. doi: 10.1111/1567-1364.12068 [DOI] [PubMed] [Google Scholar]
  • 81.Ding X, Liu Z, Su J, Yan D. Human serum inhibits adhesion and biofilm formation in Candida albicans. BMC Microbiol. 2014;14: 1–9. doi: 10.1186/1471-2180-14-80 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Bayan L, Koulivand PH, Gorji A. Garlic: a review of potential therapeutic effects. Avicenna J Phytomedicine. 2014;4: 1. [PMC free article] [PubMed] [Google Scholar]
  • 83.Mansourian A, Boojarpour N, Ashnagar S, Momen Beitollahi J, Shamshiri AR. The comparative study of antifungal activity of Syzygium aromaticum, Punica granatum and nystatin on Candida albicans; An in vitro study. J Mycol Med. 2014;24: e163–e168. doi: 10.1016/j.mycmed.2014.07.001 [DOI] [PubMed] [Google Scholar]
  • 84.Ashfaq F, Ali Q, Haider M, Hafeez M, Malik A. Therapeutic Activities of Garlic Constituent Phytochemicals. Biol Clin Sci Res J. 2021;2021: e007. Available: http://bcsrj.com/ojs/index.php/bcsrj/article/view/53 [Google Scholar]
  • 85.Vicidomini C, Roviello V, Roviello GN. Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility. Mol 2021, Vol 26, Page 1880. 2021;26: 1880. doi: 10.3390/molecules26071880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Acar A. Ameliorative effects of cape gooseberry (Physalis peruviana L.) against monosodium glutamate (MSG)–induced toxicity: genetic and biochemical approach. Environ Sci Pollut Res 2021 2814. 2021;28: 18035–18049. doi: 10.1007/s11356-020-11800-1 [DOI] [PubMed] [Google Scholar]
  • 87.Monteiro MC, de la Cruz M, Cantizani J, Moreno C, Tormo JR, Mellado E, et al. A New Approach to Drug Discovery: High-Throughput Screening of Microbial Natural Extracts against Aspergillus fumigatus Using Resazurin. 2012;17: 542–549. doi: 10.1177/1087057111433459 [DOI] [PubMed] [Google Scholar]
  • 88.Grela E, Kozłowska J, Grabowiecka A. Current methodology of MTT assay in bacteria–A review. Acta Histochem. 2018;120: 303–311. doi: 10.1016/j.acthis.2018.03.007 [DOI] [PubMed] [Google Scholar]
  • 89.Batiha GES, Alkazmi LM, Wasef LG, Beshbishy AM, Nadwa EH, Rashwan EK. Syzygium aromaticum L. (Myrtaceae): Traditional Uses, Bioactive Chemical Constituents, Pharmacological and Toxicological Activities. Biomol. 2020;10: 202. doi: 10.3390/biom10020202 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Middha SK, Goyal AK, Lokesh P, Yardi V, Mojamdar L, Keni DS, et al. Toxicological Evaluation of Emblica officinalis Fruit Extract and its Anti-inflammatory and Free Radical Scavenging Properties. Pharmacogn Mag. 2015;11: S427–S433. doi: 10.4103/0973-1296.168982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Kim JH, Seo CS, Kim SS, Ha H. Simultaneous determination of gallic acid, ellagic acid, and eugenol in syzygium aromaticum and verification of chemical antagonistic effect by the combination with curcuma aromatica using regression analysis. J Anal Methods Chem. 2013;2013. doi: 10.1155/2013/375294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Hasan MR, Islam MN, Islam MR. Phytochemistry, pharmacological activities and traditional uses of Emblica officinalis: A review. Int Curr Pharm J. 2016;5: 14–21. doi: 10.3329/ICPJ.V5I2.26441 [DOI] [Google Scholar]
  • 93.Versari C, Stoma S, Batmanov K, Llamosi A, Mroz F, Kaczmarek A, et al. Long-term tracking of budding yeast cells in brightfield microscopy: CellStar and the Evaluation Platform. J R Soc Interface. 2017;14. doi: 10.1098/rsif.2016.0705 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94.Weiland-Bräuer N, Malek I, Schmitz RA. Metagenomic quorum quenching enzymes affect biofilm formation of Candida albicans and Staphylococcus epidermidis. PLoS One. 2019;14: e0211366. doi: 10.1371/journal.pone.0211366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Messier C, Epifano F, Genovese S, Grenier D. Inhibition of Candida albicans biofilm formation and yeast-hyphal transition by 4-hydroxycordoin. Phytomedicine. 2011;18: 380–383. doi: 10.1016/j.phymed.2011.01.013 [DOI] [PubMed] [Google Scholar]
  • 96.Staniszewska M M B, K S, W K. Ultrastructure of Candida albicans pleomorphic forms: phase-contrast microscopy, scanning and transmission electron microscopy. Polish J Microbiol. 2012;61: 129–135. Available: https://europepmc.org/article/med/23163212 [PubMed] [Google Scholar]
  • 97.Yamakava T, Tomita K, Sawai J. Characteristics of Biofilms Formed by Co-Culture of Listeria monocytogenes with Pseudomonas aeruginosa at Low Temperatures and Their Sensitivity to Antibacterial Substances. Biocontrol Sci. 2018;23: 107–119. doi: 10.4265/BIO.23.107 [DOI] [PubMed] [Google Scholar]
  • 98.Quatrin PM, Verdi CM, de Souza ME, de Godoi SN, Klein B, Gundel A, et al. Antimicrobial and antibiofilm activities of nanoemulsions containing Eucalyptus globulus oil against Pseudomonas aeruginosa and Candida spp. Microb Pathog. 2017;112: 230–242. doi: 10.1016/j.micpath.2017.09.062 [DOI] [PubMed] [Google Scholar]
  • 99.Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 2001;45: 999–1007. doi: 10.1128/AAC.45.4.999-1007.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Guadalupe Virginia Nevárez-Moorillón

20 Feb 2023

PONE-D-23-01209Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of Candida albicansPLOS ONE

Dear Dr. Sadanandan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please consider the comments of both reviewers.

Please submit your revised manuscript by Apr 06 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Guadalupe Virginia Nevárez-Moorillón, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Please upload a new copy of Figure 10 as the detail is not clear. Please follow the link for more information:

https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The aim of this study was to explore the potential of spice-based antimycotics to control C. albicans biofilms. The methods and study design are appropriate for answering the research question and the experiments have appropriate control group. The statistical tests used were appropriate and correctly reported. The figures are clear and they accurately represent the results. Previous research by the authors and others has been discussed and those results have been compared to the current results. The results support the conclusions. Minor revisions are necessary:

1. Please review the English.

2. In the Abstract, please, specify what TSA means.

3. In the Introduction, please added more information about the cytotoxic effects of the Spice Extracts used in this study.

4. In addition, the cytotoxicity or biocompatibility of Spice Extracts, at the same concentrations used in this study, should be evaluated.

5. In the MM, please, specify what ICU means.

Reviewer #2: The paper by Bindu Sadanandan et al describes the effect of aqueous spice extracts on highly drug resistant extensive biofilm forming clinical isolates of Candida albicans. Taking into account the understanding of the impact of biofilms on bacterial susceptibility to antimicrobials, as well as the wide spread of resistance to antimicrobials, this topic is very important for the clinical practice.

Overall the experimental design is relevant and idea is publication-worth.

Nevertheless, the some issues should be addressed before considering for publication and paper requires the revision.

For regret the quality of figures is too low to evaluate them, the font size in some cases should be increased.

It looks a bit strange to use MTT at half-MIC concentration, in such design the assay is not informative. It would be nice to check whether the aqueous spice extracts are effective against preformed biofilms. Briefly, one should treat pre-formed biofilms with extracts for some time frames and then evaluate the residual viability of cells in biofilm with MTT.

It would be worse to quantify residual biomass on Figs 11 and 13, there are many free software for quantification of biofilms and biofilm-embedded cells from fluorescent microscopic images.

The coating of surfaces with aqueous spice extracts seems to be problematic, the reviewer recommends to change the focus to the treatment of Candida-associated mucosal (oral, vaginal) infections since the aqueous fraction will not irritate the mucosa. In this relation a some information about these infection should be added to Introduction.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 14;18(6):e0281035. doi: 10.1371/journal.pone.0281035.r002

Author response to Decision Letter 0


17 Apr 2023

RESPONSE TO THE REVIEWER’S COMMENTS

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: The manuscript has been revised to meet PLOS ONE’s style requirements.

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information.

Response: Not applicable

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Response: The manuscript does not have any blot/gel images. In all other images, originals have been provided.

4. Please upload a new copy of Figure 10 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/

Response: A better-quality Figure 10 has been uploaded.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The aim of this study was to explore the potential of spice-based antimycotics to control C. albicans biofilms. The methods and study design are appropriate for answering the research question and the experiments have appropriate control group. The statistical tests used were appropriate and correctly reported. The figures are clear and they accurately represent the results. Previous research by the authors and others has been discussed and those results have been compared to the current results. The results support the conclusions. Minor revisions are necessary:

1. Please review the English.

Response: The English has been reviewed and the manuscript has been revised accordingly.

2. In the Abstract, please, specify what TSA means.

Response: TSA has been specified as Tryptic Soy Agar in the abstract.

3. In the Introduction, please added more information about the cytotoxic effects of the Spice Extracts used in this study.

Response: Several of the spice extracts are found to be non-toxic to normal cells and toxic to cancer cells. Information regarding the cytotoxic effect of the spice extracts has been included in the introduction.

4. In addition, the cytotoxicity or biocompatibility of Spice Extracts, at the same concentrations used in this study, should be evaluated.

Response: The biocompatibility of the spice extracts has also been discussed in the introduction.

5. In the MM, please, specify what ICU means.

Response: ICU has been specified as Intensive Care Unit in the materials and methods.

Reviewer #2: The paper by Bindu Sadanandan et al describes the effect of aqueous spice extracts on highly drug resistant extensive biofilm forming clinical isolates of Candida albicans. Taking into account the understanding of the impact of biofilms on bacterial susceptibility to antimicrobials, as well as the wide spread of resistance to antimicrobials, this topic is very important for the clinical practice.

Overall the experimental design is relevant and idea is publication-worth.

Nevertheless, the some issues should be addressed before considering for publication and paper requires the revision.

For regret the quality of figures is too low to evaluate them, the font size in some cases should be increased.

Response: We have done our best to improve the quality of the figures.

It looks a bit strange to use MTT at half-MIC concentration, in such design the assay is not informative.

Response: Minimum inhibitory concentration 50 (MIC50) is the most widely used and informative measure of a drug’s efficacy. However, we have carried out MTT at MIC concentrations lower and higher than MIC50 (Fig 7).

It would be nice to check whether the aqueous spice extracts are effective against preformed biofilms. Briefly, one should treat pre-formed biofilms with extracts for some time frames and then evaluate the residual viability of cells in biofilm with MTT.

Response: We have performed experiments to check the effectiveness of garlic extract on preformed biofilm. Biofilms were grown for 24 and 48 h and then treated with garlic extract at different concentrations and incubation times and the residual viability of cells was evaluated by MTT assay. The results have been included in the results and discussion section.

It would be worse to quantify residual biomass on Figs 11 and 13, there are many free software for quantification of biofilms and biofilm-embedded cells from fluorescent microscopic images.

Response: The integrated intensity of the cultures (control and treated with spice extracts) were quantified using ImageJ. The results of the same have been included in the results and discussion section of the manuscript.

The coating of surfaces with aqueous spice extracts seems to be problematic, the reviewer recommends to change the focus to the treatment of Candida-associated mucosal (oral, vaginal) infections since the aqueous fraction will not irritate the mucosa. In this relation some information about these infections should be added to Introduction.

Response: In our study we are not trying to coat the surface with aqueous spice extract, rather inhibit the growth of Candida on surfaces using spice extracts. However as per the reviewer’s suggestion, as we are using aqueous extracts of spices, the information regarding Candida associated mucosal infections has been included in the introduction.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Decision Letter 1

Guadalupe Virginia Nevárez-Moorillón

25 Apr 2023

PONE-D-23-01209R1Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of Candida albicansPLOS ONE

Dear Dr. Sadanandan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The reviewers have commented that their suggestions have been addressed. The revised manuscript still needs modifications, mainly in the Conclusions section, which needs to be modified to comply with PLOS One guidelines. Usually, the conclusions are concrete statements based on objectives and results. Please revise.  Please submit your revised manuscript by Jun 09 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Guadalupe Virginia Nevárez-Moorillón, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

********** 

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

********** 

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 14;18(6):e0281035. doi: 10.1371/journal.pone.0281035.r004

Author response to Decision Letter 1


22 May 2023

RESPONSE TO THE REVIEWER’S COMMENTS

PONE-D-23-01209R1

Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of Candida albicans

The reviewers have commented that their suggestions have been addressed. The revised manuscript still needs modifications, mainly in the Conclusions section, which needs to be modified to comply with PLOS One guidelines. Usually, the conclusions are concrete statements based on objectives and results. Please revise.

RESPONSE: The conclusions section of the manuscipt has been revised according to the PLOS ONE guidelines.

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

RESPONSE: Minor revisions in the refernces have been made as indicated in the track changes of the manuscript.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: (No Response)

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 2

Guadalupe Virginia Nevárez-Moorillón

1 Jun 2023

Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of Candida albicans

PONE-D-23-01209R2

Dear Dr. Sadanandan,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Guadalupe Virginia Nevárez-Moorillón, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Guadalupe Virginia Nevárez-Moorillón

5 Jun 2023

PONE-D-23-01209R2

Aqueous Spice Extracts as Alternative Antimycotics to Control Highly Drug Resistant Extensive Biofilm Forming Clinical Isolates of Candida albicans

Dear Dr. Sadanandan:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Guadalupe Virginia Nevárez-Moorillón

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Lactophenol cotton blue stained C. albicans.

    (a) MTCC-3017, (b) U-427, (c) U-499, (d) U-3893, (e) M-207, (f) M-529, (g) S-470, (h) U-2647, (i) U-3800, (j) U-3713, (k) D4 at 24 h.

    (TIF)

    S2 Fig. Germ tube formation in C. albicans isolates.

    (a) MTCC-3017, (b) M-207, (c) M-529, (d) S-470, (e) U-2647, (f) U-3713, (g) U-3800, (h) U-3893, (i) U-427, (j) U-499, and (k) D-4. The arrows indicate the germ tube formed by the isolates.

    (TIF)

    S3 Fig. C. albicans isolates grown on CHROMagar medium.

    MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 were cultured.

    (TIF)

    S4 Fig. Biofilm tube test for C. albicans isolates.

    MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4.

    (TIF)

    S5 Fig. Point inoculation of C. albicans isolates on TSA medium.

    (a) U-427, (b) U-499, (c) U-2647, (d) U-3800, (e) U-3893, (f) U-3713, (g) M-529, and (h) D-4 at 16 h.

    (TIF)

    S6 Fig. Point inoculation of C. albicans isolates on YEPD medium.

    MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 at 16 h.

    (TIF)

    S7 Fig. Point inoculation of C. albicans isolates on SDA medium.

    MTCC-3017, M-207, M-529, S-470, U-2647, U-3713, U-3800, U-3893, U-427, U-499, and D-4 at 16 h.

    (TIF)

    S8 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in MYB medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S9 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in YEPD medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S10 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in PDB medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S11 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in SDB medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S12 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in YMB medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S13 Fig. Growth of C. albicans clinical isolates on FBS and non FBS coated 96 well microtiter plate in RPMI-1640 medium.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S14 Fig. Growth profile of C. albicans isolates in RPMI-1640 for 0-72h.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S15 Fig. Growth profile of C. albicans isolates in Yeast Extract Peptone Dextrose for 0-72h.

    All values are expressed as mean and standard deviation. The experiment was performed in triplicate.

    (TIF)

    S16 Fig. Screening of spice extracts.

    (a) (1) Clove (2) Papaya seeds (3) Indian Gooseberry (4) Onion (5) Water as control, (b) (1) Pudina (2) Pepper (3) Lemon (4) Garlic (5) Water as control, (c) Papaya leaf (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (d) Neem (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (e) Turmeric (1) 100 mgmL-1 (2) 250 mgmL-1 (3) 500 mgmL-1 (4) 750 mgmL-1 (5) 1000 mgmL-1 (6) 2000 mgmL-1 (7) Water as control, (f) Swallow root (1) 100 mgmL-1 (2) 150 mgmL-1 (3) 250 mgmL-1 (4) 500 mgmL-1 (5) Water as control. (A) C. albicans M-207 and (B) C. albicans S-470 biofilm.

    (TIF)

    S17 Fig. Zones of inhibition (mm) in well diffusion showing antimicrobial activity of garlic, clove and Indian gooseberry on MHA.

    (A) C. albicans M-207 and (B) C. albicans S-470 by solvent extraction. (a) (1) Clove + Petroleum ether, (2) Clove + Ethyl Acetate, (3) Garlic + Petroleum ether, (4) Garlic + Ethyl Acetate, (5) Indian Gooseberry + Ethyl Acetate, (6) Indian Gooseberry + Petroleum ether, (7) Control (Water), (b) (1) Garlic + Chloroform, (2) Indian Gooseberry + Chloroform, (3) Clove + Chloroform, (4) Garlic + Methanol, (5) Indian Gooseberry + Methanol, (6) Clove + Methanol, (7) Control (Water) (c) (1) Garlic + Ethanol, (2) Indian Gooseberry + Ethanol, (3) Clove + Ethanol, (4) Garlic + Butanol, (5) Indian Gooseberry + Butanol, (6) Clove + Butanol, (7) Control (Water).

    (TIF)

    S18 Fig. Zones of inhibition (mm) in disc diffusion showing antimicrobial activity of garlic, clove and Indian gooseberry on MHA.

    (A) C. albicans M-207 and (B) C. albicans S-470 by solvent extraction. (a) (1) Clove + Petroleum ether, (2) Clove + Ethyl Acetate, (3) Garlic + Petroleum ether, (4) Garlic + Ethyl Acetate, (5) Indian Gooseberry + Ethyl Acetate, (6) Indian Gooseberry + Petroleum ether, (7) Control (Water), (b) (1) Garlic + Chloroform, (2) Indian Gooseberry + Chloroform, (3) Clove + Chloroform, (4) Garlic + Methanol, (5) Indian Gooseberry + Methanol, (6) Clove + Methanol, (7) Control (Water (c) (1) Garlic + Ethanol, (2) Indian Gooseberry + Ethanol, (3) Clove + Ethanol,(4) Garlic + Butanol, (5) Indian Gooseberry + Butanol, (6) Clove + Butanol, (7) Control (Water).

    (TIF)

    S19 Fig. HPTLC of aqueous extracts of garlic, clove and Indian gooseberry.

    (A) HPTLC of Aqueous garlic extract indicated as ASP (Allium sativum Pulp)—Track 1: ASP (Aq. extract); Track 2: Alliin standard, (B) HPTLC of Aqueous clove extract indicated as SAFB (Syzygium aromaticum Flower Bud)—Track 1: SAFB; Track 2: Ellagic acid standard, (C) HPTLC of Aqueous gooseberry extract indicated as EOF (Emblica officinalis Fruit)—Track 1: EOF; Track 2: Gallic acid standard, at (a) 254 nm and (b) 366 nm.

    (TIF)

    S20 Fig. Microscopic images of crystal violet stained C. albicans.

    (A) C. albicans M-207, (B) C. albicans S-470 induced on coverslip in TSB medium for (a) 24h, (b) 48h, (c) 72h, (d) 96h, (e) 120h, (f) 12days at 40X & 100X magnifications.

    (TIF)

    S21 Fig. Microscopic images of Lactophenol cotton blue stained stained C. albicans.

    (A) C. albicans M-207, (B) C. albicans S-470 induced on coverslip in TSB medium for (a) 24h, (b) 48h, (c) 72h, (d) 96h, (e) 120h, (f) 12days at 40X & 100X magnifications.

    (TIF)

    S1 Table. Zone of inhibition for solvent extractions of garlic, clove, and Indian gooseberry by well diffusion method.

    The solvents used were petroleum ether, ethyl acetate, chloroform, methanol, ethanol, and butanol.

    (PDF)

    Attachment

    Submitted filename: Response to reviewers.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES